February 5, 2024
4DMT’s Gene Therapy Reduces Eylea Injections, Advancing Plans for Phase 3 Trial in Wet AMD
Glycogen storage disease type II, 4DMT, gene therapy, Trial Phase
Updated: Novo Holdings pays $16.5B to take Catalent private and sells three manufacturing sites to Novo Nordisk
Holdings, Nordisk, deal, Acquisition (action), Investments
Takeda Appoints Former CRISPR CMO Phuong Khanh (PK) Morrow to Lead Oncology R&D Amidst Pipeline Pruning
Clustered Regularly Interspaced Short Palindromic Repeats, PK